The multimodal treatment of acromegaly: Current status and future perspectives

Endocrine, Metabolic and Immune Disorders - Drug Targets

Volumn 14, Issue 3, 2014, Pages 169-181

  Espinosa, Etual ^a   Ramírez, Claudia ^a,b   Mercado, Moises ^a,b  

^a HOSPITAL DE ESPECIALIDADES   (Mexico)

^b AMERICAN BRITISH COWDRAY MEDICAL CENTER   (Mexico)

Author keywords

Acromegaly; Cabergoline; Dopamine agonists; GH; IGF 1; Lanreotide; Octreotide; Pegvisomant; Radiation therapy; Somatostatin analogs

Indexed keywords

CHOLECYSTOKININ; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; GROWTH HORMONE; GROWTH HORMONE RECEPTOR; GROWTH HORMONE RELEASING FACTOR; KI 67 ANTIGEN; PEGVISOMANT; PEPTIDE HORMONE RECEPTOR BLOCKING AGENT; SECRETIN; SOMATOMEDIN C; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR 1; SOMATOSTATIN RECEPTOR 2; SOMATOSTATIN RECEPTOR 3; SOMATOSTATIN RECEPTOR 4; SOMATOSTATIN RECEPTOR 5;

ACROMEGALY; ARTHRALGIA; ARTICLE; CANCER RADIOTHERAPY; CANCER RISK; DEPRESSION; DIABETES MELLITUS; FATIGUE; HEADACHE; HUMAN; HYPERHIDROSIS; HYPERTENSION; HYPOPHYSIS ADENOMA; LIFE EXPECTANCY; META ANALYSIS (TOPIC); MULTIMODALITY CANCER THERAPY; PHASE 2 CLINICAL TRIAL (TOPIC); PREVALENCE; QUALITY OF LIFE; SEXUAL DYSFUNCTION; TRANSSPHENOIDAL SURGERY;

EID: 84916612073     PISSN: 18715303     EISSN: 22123873     Source Type: Journal    
DOI: 10.2174/1871530314666140609110308     Document Type: Article

References (139)

1. Melmed, S. (2009) Acromegaly: Pathogenesis and treatment. J. Clin. Invest, 119, 3189-3200.
2. Melmed, S. (2006) Acromegaly. N Engl. J. Med., 335, 2258-2273.
3. Melmed, S. (2011) Pathogenesis of pituitary tumors. Nat. Rev. Endocrinol., 7, 257-266.
4. Holdaway, I.M. and Rajasoorya, C. (1999) Epidemiology of acromegaly. Pituitary, 2, 29-41.
5. Melmed, S.; Colao, A.; Barkan, A.; Molitch, M.; Grossman, A.B.; Kleinberg, D.; Clemmons, D.; Chanson, P.; Laws, E.; Schlechte, J.; Vance, M.L.; Ho, K. and Giustina, A. (2009) Guidelines for acromegaly management: An Update. J. Clin. Endocrinol. Metab., 94, 1509-1517.
6. Giustina, A.; Chanson, P.; Bronstein, M.D.; Klibanski, A.; Lamberts, S.; Casanueva, F.F.; Trainer, P.; Ghigo, E.; Ho, K. and Melmed, S. (2010) A consensus on criteria for cure in acromegaly. J. Clin. Endocrinol. Metab., 95, 3141-3148.
7. Guinto, G.; Abdo, M.; Zepeda, E.; Arechiga, N.; and Mercado, M. (2012) Acromegaly: Role of surgery in the therapeutic armamentarium. Intern. J. Endocrinol., 2012, 306094.
8. Lissett, C.A.; Peacey, S.R.; Laing, I.; Tetlow, R.; Davis, J.R. and Shalet, S.M. (1998) The outcome of surgery for acromegaly: the need for a specialist pituitary surgeon for all types of GH-secreting adenomas. Clin. Endocrinol., 49, 653-7.
9. Wang, Y.Y.; Higham, C.; Kearney, T.; Davis, J.R.; Trainer, P. and Gnanalingham, K.K. (2012) Acromegaly surgery in Manchester revisited-the impact of reducing surgeon numbers and the 2010 consensus guidelines for disease remission. Clin. Endocrinol., 76, 399-406.
10. Swearingen, B.; Barker, F.G.; Katznelson, L.; Biller, B.M.; Grinspoon, S.; Klibanski, A.; Moayeri, N.; Black, P.M. and Zervas, N.T. (1998) Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J. Clin. Endocrinol. Metab., 83, 3419-3426.
11. Nomikos, P.; Buchfelder, M. and Fahlbusch, R. (2005) The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical cure. Eur. J. Endocrinol., 152, 379-387.
12. Espinosa-de-los-Monteros, A.L.; Sosa, E.; Cheng, S.; Ochoa, R.; Sandoval, C.; Guinto, G.; Mendoza, V.; Hernández, I.; Molina, M. and Mercado, M. (2006) Biochemical evaluation of disease activity after pituitary surgery in acromegaly: a critical analysis of patients who spontaneously change disease status. Clin. Endocrinol., 64, 245-249.
13. Wagenmakers, M.A.; Neeta-Maier, R.T.; van Linder, E.J.; Pieter's, G.F.; Grotenhuis, A.J. and Hermus, A.R. (2011) Results of endoscopic transsphenoidal surgery in 40 patients with growth hormonesecreting macroadenoma. Acta. Neurochir., 153, 1391-1399.
14. Starke, R.M.; Raper, D.M.; Payne, S.C.; Vance, M.L.; Oldfield, E.J. and Jane, J.A. Jr. (2013) Endoscopic vs. microscopic transsphenoidal surgery for acromegaly: outcomes in a concurrent series of patients using modern criteria for remission. J. Clin. Endocrinol. Metab., 98, 3190-3198.
15. Roelfsema, F.; Biermasz, N.R. and Pereira, A.M. (2012) Clinical factors involved in the recurrence of pituitary adenomas after surgical remission: a structured review and meta-analysis. Pituitary, 15, 71-83.
16. Espinosa de los Monteros, A.L.; González, B.; Vargas, G.; Sosa, E.; Guinto, G. and Mercado, M. (2009) Surgical re-intervention in acromegaly: Is it still worth trying? Endocr. Pract., 15, 431-437.
17. Wilson, T.J; McKean, E.L; Barkan, A.L; Chandler, W.F; and Sullivan, S.E. (2013) Repeat endoscopic transsphenoidal surgery for acromegaly: remission and complications. Pituitary, 16, 459-464.
18. Costa, A.C.; Rossi, A.; Matinelli, C.E. Jr.; Manchado, H.R. and Moreira, A.C. (2002) Assessment of disease activity in treated acromegalic patients using a sensitive GH assay: should we achieve strict GH levels for a biochemical cure? J. Clin. Endocrinol. Metab., 87, 3142-3147.
19. Espinosa-de-los Monteros, A.L.; Mercado, M.; Sosa, E.; Lizama, O.; Guinto, G.; López-Félix, B.; García, O.; Hernández, I.; Ovalle, A. and Mendoza, V. (2002) Changing biochemical patterns of insulin-like growth factor glucose-suppressed growth hormone and I levels after pituitary surgery in patients with acromegaly. J. Neurosurg., 97, 287-92.
20. Alexopoulou, O.; Bex, M.; Abs, R.; T'Sjoen, G.; Velkeniers, B. and Maiter, D. (2008) Divergence between growth hormone and insulin-like growth factor 1 concentrations in the follow up of acromegaly. J. Clin. Endocrinol. Metab., 93, 1324-1330.
21. Gillam, M.P.; Molitch, M.E.; Lombardi, G. and Colao, A. (2006) Advances in the treatment of prolactinomas. Endocr. Rev., 27, 485- 534.
22. Leung, K.C.; Johannsson, G.; Leung, G.M. and Ho, K.K. (2004) Estrogen regulation of growth hormone action. Endocr. Rev., 25, 693-721.
23. Shimon, I. and Barkan, A. (2012) Estrogen treatment for acromegaly. Pituitary, 15, 601-607.
24. Dimaraki, E.V.; Symons, K.V. and Barkan, A.L. (2004) Raloxifene decreases serum IGF-I in male patients with active acromegaly. Eur. J. Endocrinol., 150, 481-487.
25. Besser, G.M.; Wass, J.A. and Thorner, M.O. (1978) Acromegaly: results of long-term treatment with bromocriptine. Acta. Endocrinol. Supplement., 216, 187-198.
26. Besser, G.M.; Wass, J.A. and Thorner, M.O. (1980) Bromocriptine in the medical management of acromegaly. Adv. Biochem. Psychopharmacol., 23, 191-198.
27. Espinosa-de-los-Monteros, A.L.; Carrasco, C.A.; Reza Albarrán, A.A.; Gadelha, M.R.; Abreu, A. and Mercado, M. (2014) The role of primary pharmacological therapy in acromegaly. Pituitary, 17(suppl 1), S4-S10
28. Bronstein, M.; Bruno, O.D.; Abreu, A.; Mangupli, R. and Mercado, M. (2014) A practical approach to acromegaly management in Latinamerica. Pituitary, 17(suppl 1), 30-35.
29. Brazeu, P.; Vale, W.; Burgus, R.; Ling, N.; Botheher, M.; Rivier, J. and Guillemin, R. (1973) Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary GH. Science, 179, 77-79.
30. Mayo, K.E.; Miller, T.; De Almeida, V.; Godfrey, P.; Zheng, J. and Cunha, S.R. (2000) Regulation of the pituitary somatotroph cell by GHRH and its receptor. Recent Progr. Horm. Res., 55, 237-66.
31. Tannenbaum, G.S.; Epelbaum, J. and Bowers, C.Y. (2003) Interrelationship between the novel peptide ghrelin and somatostatin/GHRH in the regulation of pulsatile GH secretion. Endocrinology, 144, 967-974.
32. Yamada, T.; Soll, A.H.; Park, J.; and Elashoff, J. (1984) Autonomic regulation of somatostatin release: Studies with primary cultures of canine fundic mucosal cells. Am. J. Physiol., 247, G567-G573.
33. Zingg, H.H. and Patel, Y.C. (1980) Processing of somatostatin precursors: evidence of enzymatic cleavage by hypothalamic extract. Biochem. Biophys. Res. Com., 93, 1274-1279.
34. Gorden, P.; Comi, R.J.; Maton, P.N. and Go, V.L. (1989) NIH Conference: Somatostatin and somatostatin analogue (SMS 201- 995) in treatment of hormone-secreting tumors of the pituitary and gastrointestinal tract and non-neoplastic diseases of the gut. Ann. Intern. Med., 110, 35-50.
35. Reisine, T. and Bell, G.I. (1995) Molecular biology of somatostatin receptors. Endocr. Rev., 16, 427-442.
36. Patel, Y.C. (1997) Molecular pharmacology of somatostatin receptor subtypes. J. Endocrinol. Invest., 20, 348-367.
37. Tulipano, G. and Schulz, S. (2007) Novel insights in somatostatin receptor physiology. Eur. J. Endocrinol., 153, S3-S11.
38. Pfeiffer, M.; Koch, T.; Schröder, H.; Klutzny, M.; Kirscht, S.; Kreienkamp, H.J; Höllt, V. and Schulz, S. (2001) Homo- and heterodimerization of somatostatin receptor subtypes. Inactivation of sst3 receptor function by heterodimerization with sst2a. J. Biol. Chem., 276, 14027-14036.
39. Pfeiffer, M.; Koch, T.; Schroder, H.; Laugsch, M.; Höllt, V. and Schulz, S. (2002) Heterodimerization of somatostatin and opioid receptors modulates phosphorylation, internalization and desensitization J. Biol. Chem., 277, 19762-19772.
40. Chiodini, P.G.; Cozzi, R.; Dallabonzana, D.; Oppizzi, G.; Verde, G.; Petroncini, M.; Liuzzi, A. and del Pozo, E. (1987) Medical treatment of acromegaly with SMS 201-995, a somatostatin analog: a comparison with bromocriptine. J. Clin. Endocrinol. Metab., 64, 447-453.
41. Lamberts, S.W.; van der Lely, A.J.; de Herder, W.W. and Hofland, L.J. (1996) Octreotide. N. Engl. J. Med., 334, 246-254.
42. Heron, I.; Thomas, F.; Dero, M.; Gancel, A.; Ruiz, J.M.; Schatz, B. and Kuhn, J.M. (1993) Pharmacokinetics of a long-acting formulation of the new somatostatin analog BIM 23014 in patients with acromegaly. J. Clin. Endocrinol. Metab., 76, 721-727.
43. Jaquet, P.; Saveanu, A.; Gunz, G.; Fina, F.; Zamora, A.J.; Grino, M.; Culler, M.D.; Moreau, J.P.; Enjalbert, A. and Ouafik, L.H. (2000) Human somatostatin receptor subtypes in acromegaly: distinct patterns of messenger ribonucleic acid expression and hormone suppression identify different tumoral phenotypes. J. Clin. Endocrinol. Metab., 85, 781-792.
44. Van der Hoek, J.; Lamberts, S.W.J. and Hofland, L.J. (2007) Preclinical and clinical experiences with the role of somatostatin receptors in the treatment of pituitary adenomas. Eur. J. Endocrinol., 156, S45-S61.
45. Colao, A.; Ferone, D.; Lastoria, S.; Marzullo, P.; Cerbone, G.; Di Sarno, A.; Longobardi, S.; Merola, B.; Salvatore, M. and Lombardi, G. (1996) Prediction of efficacy of octreotide therapy in patients with acromegaly. J. Clin. Endocrinol. Metab., 81, 2356-2362.
46. Legovini, P.; De Menis, E.; Billeci, D.; Conti, B.; Zoli, P. and Conte, N. (1997) 111-Indium-pentetreotide pituitary scintigraphy and hormonal responses to octreotide in acromegalic patients. J. Endocrinol. Invest., 20, 424-428.
47. Taboada, G.F.; Luque, R.M.; Neto, L.V.; Machado Ede, O.; Sbaffi, B.C.; Domingues, R.C.; Marcondes, J.B.; Chimelli, L.M.; Fontes, R.; Niemeyer, P.; de Carvalho, D.P.; Kineman, R.D. and Gadelha, M.R. (2008) Quantitative analysis of somatostatin receptor subtypes (1-5) gene expression levels in somatotropinomas and correlation to in vivo and tumor volume responses to treatment to octreotide LAR. Eur. J. Endocrinol., 158, 295-303.
48. Ferone, G.; de Herder, W.W.; Pivonello, R.; Kros, J.M.; van Koetsveld, P.M.; de Jong, T.; Minuto, F.; Colao, A; Lamberts, S.W. and Hofland, L.J. (2008) Correlation of in vitro and in vivo somatotrophic adenoma responsiveness to somatostatin analogues and dopamine agonists with immunohistochemical evaluation of somatostatin and dopamine receptors and electron microscopy. J. Clin. Endocrinol. Metab., 93, 1412-1417.
49. Plöckinger, U.; Albrecht, S.; Mawrin, C.; Saeger, W.; Buchfelder, M.; Petersenn, S. and Schulz, S. (2008) Selective loss of somatostatin receptor 2 in octreotide-resistant growth hormonesecreting adenomas. J. Clin. Endocrinol. Metab., 93, 1203-1210.
50. Gatto, F.; Feelders, R.A.; van der Pas, R.; Kros, J.M.; Waaijers, M.; Sprij-Mooij, D.; Neggers, S.J.; van der Lelij, A.J.; Minuto, F.; Lamberts, S.W.; de Herder, W.W.; Ferone, D and Hofland, L.J. (2013) Immunoreactivity score using an anti-sst2A receptor monoclonal antibody strongly predicts the biochemical response to adjuvant treatment with somatostatin analogs in acromegaly. J. Clin. Endocrinol. Metab., 98, E66-E77.
51. Wildemberg, L.A.; Neto, L.V.; Costa, D.F.; Nasciuti, L.E.; Takiya, C.M.; Alves, L.M.; Rebora, A.; Minuto, F.; Ferone, D. and Gadelha, M.R. (2013) Low somatostatin receptor subtype 2, but not dopamine receptor subtype 2 expression predicts the lack of biochemical response of somatotropinomas to treatment with somatostatin analogs. J. Endocrinol. Invest., 36, 38-43.
52. Colao, A.; Auriemma, R.S.; Lombardi, G. and Pivonello, R. (2011) Resistance to somatostatin analogs in acromegaly. Endocr. Rev., 32, 247-271.
53. Barlier, A.; Gunz, G.; Zamora, A.J.; Morange-Ramos, I.; Figarella- Branger, D.; Dufour, H.; Enjalbert, A. and Jaquet, P. (1998) Prognostic and therapeutic consequences of Gsaamutations in somatotroph adenomas. J. Clin. Endocrinol. Metab., 83, 1604-1610.
54. Mendoza, V.; Sosa, E.; Espinosa de los Monteros, A.L.; Salcedo, M.; Guinto, G.; Cheng, S.; Sandoval, C. and Mercado, M. (2005) GSPGGmutations in Mexican patients with acromegaly: potential impact on long-term prognosis. GH & IGF Res, 15, 28-32.
55. Freda, P.U.; Chung, W.K.; Matsuoka, N.; Walsh, J.E.; Kanibir, M.N.; Kleinman, G.; Wang, Y.; Bruce, J.N. and Post, K.D. (2007) Analysis of GNAS mutations in 60 growth hormone secreting pituitary tumors: correlation with clinical and pathological characteristics and surgical outcome based on highly sensitive GH and IGF-1 criteria for remission. Pituitary, 10, 275-282.
56. Larkin, S.; Reddy, R.; Karavitaki, R.; Cudlip, S.; Wass, J. And Ansorge, O. (2013) Granulation pattern but no GSP or GHR mutation is associated with clinical characteristics in somatostatinnaïve patients with somatotroph adenomas. European J. Endocrinol., 168, 491-499.
57. Bhayana, S.; Booth, G.L.; Asa, S.L.; Kovacs, K. and Ezzat, S. (2005) The implications of somatotroph adenoma phenotype to somatostatin analog responsiveness in acromegaly. J. Clin. Endocrinol. Metab., 90, 6290-6299.
58. Fusco, A.; Zatelli, M.C.; Bianchi, A.; Cimino, V.; Tilaro, L.; Veltri, F.; Angelini, F.; Lauriola, L.; Vellone, V.; Doglietto, F.; Ambrosio, M.R.; Maira, G.; Giustina, A.; degli Uberti, E.C.; Pontecorvi, A. and De Marinis, L. (2008) Prognostic significance of the Ki-67 labeling index in growth hormone-secreting pituitary adenomas. J. Clin. Endocrinol. Metab., 93, 2746-2750.
59. Kasuki, L; Wildemberg, L.E; Neto, L.V; Marcondes, J; Takiya, C.M. and Gadelha, M.R. (2013) Ki-67 is a predictor of acromegaly control with octreotide LAR independent of SSTR2 status and relates to cytokeratin pattern. European J. Endocrinol., 169, 217- 223.
60. Beckers, A; Aaltonen L.A; Daly, A.F. and Karhu A. (2013) Familial isolated pituitary adenoma predisposition due to mutations in the aryl hydrocarbon receptor interacting protein (AIP) gene. Endocr. Rev., 34, 239-277.
61. Cazzabat, L; Bouligand, J; Salenave, S; Bernier, M; Gaillard, S; Parker, F; Young, J; Guichon-Mantel, A; and Chanson, P. (2012) Germline AIP mutations in apparently sporadic pituitary adenomas. Prevalence in a prospective sinlge-center cohort of 443 patients. J. Clin. Endocrinol. Metab., 97, E663-E670.
62. Kasuki, L; Viera Neto, L; Wildemberg, L.E; Machado Colli, L; de Castro, M; Takiya, C.M; and Gadelha, M.R. (2012) AIP expression in sporadic somatotropinomas is a predictor of the response to octreotide LAR therapy independent of SSTR2 expression. Endocr. Rel. Cancer., 19, L25-L29.
63. Peterssen, H.; Bizec, J.C.; Schuetz, H. and Delporte, M.L. (2011) Pharmacokinetic and technical comparison of sandostatin LAR and other formulations of long-acting octreotide. BMC Res. Notes, 4, 344.
64. Troconiz, I.F.; Cendros, J.M.; Peraire, C.; Ramis, J.; Garrido, M.J.; Boscani, P.F. and Obach, R. (2009) Population pharmacokinetic analysis of lanreotide autogel in healthy subjects: Evidence for injection interval of up to two months. Clin. Pharmacokinet., 48, 51-62.
65. Andries, M.; Glintborg, D.; Kvistborg, A.; Hagen, C. and Andersen, M. (2008) A 12-month, randomized cross-over study on the effects of lanreotide autogel and octreotide long acting repeatable on GH and IGF-1 levels in acromegaly. Clin. Endocrinol., 68, 473-480.
66. Salvatori, R.; Woodmansee, W.W.; Molitch, M.; Gordon, M.B. and Lomax, K.G. (2013) Lanreotide extended-release, aqueous gel formulation injected by patient, partner or health care provider in patients with acromegaly in the United States: 1-year data from the SODA registry. Pituitary, 17, 13-21.
67. Melmed, S.; Cook, D.; Schopohl, J.; Goth, M.I.; Lam, K.S. and Marek, J. (2010) Rapid and sustained reductions of serum growth hormone and insulin-like growth factor 1 in patients with acromegaly receiving lanreotide autogel therapy: a randomized, placebo-controlled, multicenter study with a 52 week open extension. Pituitary, 13, 18-28.
68. Davies, P.H.; Stewart, S.E.; Lancranjan, L.; Sheppard, M.C. and Stewart, P.M. (1998) Long-term therapy with long-acting octreotide (Sandostatin-LAR) for the management of acromegaly. Clin. Endocrinol., 48, 311-316.
69. Caron, P.; Beckers, A.; Cullen, D.R.; Goth, M.I.; Gutt, B.; Laurberg, P.; Pico, A.M.; Valimaki, M. and Zgliczynski, W. (2002) Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in the management of acromegaly. J. Clin. Endocrinol. Metab., 87, 99-104.
70. Bevan, J.S.; Atkin, S.L.; Atkinson, A.B.; Bouloux, P.M.; Hanna, F.; Harris P.E., James, R.A.; McConnell, M.; Roberts, G.A.; Scanlon, M.F.; Stewart, P.M.; Teasdale, E.; Turner, H.E.; Wass, J.A. and Wardlaw, J.M. (2002) Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size. J. Clin. Endocrinol. Metab., 87, 4554-4563.
71. Colao, A.; Pivonello, R.; Rosato, F.; Tita, P.; De Menis, E.; Barreca, A.; Ferrara, R.; Mainini, F.; Arosio, M. and Lombardi, G. (2002) First-line octreotide-LAR therapy induces tumor shrinkage and control hormone excess in patients with acromegaly: results from an open, prospective, multicentre trial. Clin. Endocrinol., 64, 342-352.
72. Cozzi, R.; Attanasio, R.; Montini, M; Pagani, G.; Lasio, G.; Lodrini, S.; Barausse, M.; Albizzi, M.; Dallabonzana, D. and Pedroncelli, A.M. (2003) Four-year treatment with octreotide-longacting repeatable in 110 acromegalic patients: predictive value of short-term results? J. Clin. Endocrinol. Metab., 88, 3090-3098.
73. Cozzi, R.; Montini, M.; Attanasio, R.; Albizzi, M.; Lasio, G.; Lodrini, S.; Doneda, P.; Cortesi, L. and Pagani, G. (2006) Primary treatment of acromegaly with octreotide LAR: a long-term (up to nine years) prospective study of its efficacy in the control of disease activity and tumor shrinkage. J. Clin. Endocrinol. Metab., 91, 1397-1403.
74. Colao, A.; Pivonello, R.; Auriemma, R.S.; Briganti, F.; Galdiero, M.; Tortora, F.; Caranci, F.; Cirillo, S. and Lombardi, G. (2006) Predictors of tumor shrinkage after primary therapy with somatostatin analogues in acromegaly: a prospective in 99 patients. J. Clin. Endocrinol. Metab., 91, 2112-2118.
75. Chanson, P.; Borzon-Chazot, F.; Kuhn, J.M.; Blumberg, J.; Maisonobe, P. and Delemer, B. (2008) Control of IGF-1 levels with titrated dose of lanreotide autogel over 48 weeks in patients with acromegaly. Clin. Endocrinol., 69, 299-305.
76. Colao, A.; Auriemma, R.S.; Galdiero, M.; Lombardi, G. and Pivonello, R. (2009) Effects of initial therapy for five years with somatostatin analogs for acromegaly on growth hormone and insulin-like growth factor-1 leveles tumor shrinkage and cardiovascular disease: a prospective study. J. Clin. Endocrinol. Metab., 94, 3746-3756.
77. Mercado, M.; Borges, F.; Bouterfa, H.; Chang, T.C.; Chervin, A.; Farrall, A.J.; Patocs, A.; Petersenn, S.; Podoba, J.; Safari, M. and Wardlaw, J. (2007) A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly. Clin. Endocrinol., 66, 859-868.
78. Bevan, J.S. (2005) The anti-tumoral effects of somatostatin analog therapy in acromegaly. J. Clin. Endocrinol. Metab., 90, 1856-1863.
79. Giustina, A.; Mazziotti, G.; Torri, V.; Spinello, M.; Floriani. I. and Melmed, S. (2012) Meta-analysis on the effects of octreotide on tumor mass in acromegaly. PloS One, 7, 336411.
80. Sosa, E.; Espinosa-de-los-Monteros, A.L.; González, B.; Vargas, G. and Mercado, M. (2008) Tratamiento de la acromegalia con octreótido LAR. Rev. Med. IMSS, 46, 205-212.
81. Colao, A.; Ferone, D.; Marzullo, P.; Cappabianca, P.; Cirillo, S.; Boerlin, V.; Lancranjan, I; and Lombardi, G. (2001) Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly. J. Clin. Endocrinol. Metab., 86, 2779-2786.
82. Colao, A.; Attanasio, R.; Pivonello, R.; Cappabianca, P.; Cavallo, L.M.; Lasio, G.; Lodrini, A.; Lombardi, G. and Cozzi, R. (2006) Partial surgical removal of growth hormone-secreting pituitary tumors enhances the response to somatostatin analogs in acromegaly. J. Clin. Endocrinol. Metab., 91, 85-92.
83. Jallad, R.S.; Musolino, N.R.; Kodaira, S.; Cescato, V.A. and Bronstein, M.D. (2007) Does partial surgical tumour removal influence the response to octreotide-LAR in acromegalic patients previously resistant to somatostatin analogue. Clin. Endocrinol., 67, 310-315.
84. Giustina, A.; Chanson, P.; Kleinberg, D.; Bronstein, M.D.; Clemmons, D.R.; Klibanski, A.; van der Lely, A.J.; Strasburger, C.J.; Lamberts, S.W.; Ho, K.K.; Casanueva, F.F. and Melmed, M. (2014) Expert Consensus Document: A consensus on the medical treatment of acromegaly. Nat. Rev. Endocrinol., 10, 243-248.
85. Biermasz, N.R.; van den Oever, N.C.; Frölich, M.; Arias, A.M.; Smit, J.W.; Romijn, J.A. and Roelfsema, F. (2003) Sandostatin LAR in acromegaly: a 6-week injection interval suppresses GH secretion as effectively as a 4-week interval. Clin. Endocrinol., 58, 288-295.
86. Turner, H.E.; Thornton-Jones, V.A. and Wass, J.A. (2004) Systematic dose-extension of octreotide LAR: the importance of individual tailoring of treatment in patients with acromegaly. Clin. Endocrinol., 61, 224-231.
87. Espinosa-de-los-Monteros, A.L.; Gonzalez, B.; Vargas, G.; Sosa, E. and Mercado, M. (2014) Octreotide LAR treatment of acromegaly in "real life": Long-term outcome at a tertiary care center. Pituitary[Epub ahead of print].
88. Carlsen, S.M.; Lund-Johansen, M.; Schreiner, T.; Aanderud, S.; Johannesen, O.; Svartberg, J.; Cooper, J.G.; Hald, J.K.; Fougner, S.L. and Bollerslev, J. (2008) Preoperative octreotide treatment in newly diagnosed patients with macroadenomas increases cure short-term postoperative rates: a prospective, randomized trial. J. Clin. Endocrinol. Metab., 93, 2984-2990.
89. Mao, Z.G.; Zhu, Y.H.; Wang, D.Y.; Zhou, J.; He, D.S.; Lan, H.; Luo, B.N. and Wang, H.J. (2010) Preoperative lanreotide treatment in acromegalic patients with macroadenomas increases sort-term postoperative cure rates: a prospective, randomized trial. Eur. J. Endocrinol., 162, 661-666.
90. Stewart, P.M.; Stewart, S.E.; Clark, P.M. and Sheppard, M.C. (1999) Clinical and biochemical response following withdrawal of a long-acting depot injection form of octreotide (Sandostatin LAR). Clin. Endocrinol., 50, 295-299.
91. Lorcy, Y.; Dejarger, S. and Chanson, O.P. (2000) The course of GH and IGF-1 levels following withdrawal of long-acting octreotide in acromegaly. Pituitary, 3, 193-197.
92. Ronchi, C.L.; Rizzo, E.; Lania, A.G.; Pivonello, R.; Grotolli, S.; Colao, A.; Ghigo, E.; Spada, A.; Arosio, M. and Beck-Peckos, P. (2008) Preliminary data on biochemical remission of acromegaly after somatostatin analogs withdrawal. Eur. J. Endocrinol., 158, 19-25.
93. Ramirez, C.; Vargas, G.; González, B.; Grossman, A.; Rábago, J.; Sosa, E.; Espinosa de los Monteros, A.L. and Mercado, M. (2012) Discontinuation of octreotide LAR after successful treatment of patients with acromegaly: Is it worth trying? Eur. J. Endocrinol., 166, 21-26.
94. Vilar, L.; Fleseriu, M.; Naves, L.A.; Albuquerque, J.L.; Gadelha, P.S.; Dos Santos Faria, M.; Nascimento, G.C.; Montenegro, R.M. Jr. and Montenegro, R.M. (2014) Can we predict long-term remission after somatostatin analog withdrawal in patients with acromegaly? Results from a multicenter prospective trial. Endocrine[Epub ahead of print].
95. Luciani, P.; Gelmini, S.; Ferante, E.; Lania, A.; Benvenuti, S.; Mantovani, G.; Cellai, F.; Ammanatti, F.; Spada, A.; Serio, M. and Peri, A. (2005) Expression of the anti-apoptotic gene seladin-1 and octreotide-induced apoptosis in growth hormone-secreting and nonfunctioning pituitary adenomas. J. Clin. Endocrinol. Metab., 90, 6156-6161.
96. Hofland, L.J.; van der Hoek, J. and van Koetsveld, P.M. (2004) The novel somatostatin analog SOM230 is a potent inhibitor of hormone release of growth hormone- and prolacitn-secreting pituitary adenomas in vitro. J. Clin. Endocrinol. Metab., 89, 1577- 1585.
97. Petersenn, S.; Schopohl, A.; Barkan, A.; Mohideen, P.; Colao, A.; Abs, R.; Buchelt, A.; Ho, Y.Y.; Hu, K.; Farrall, A.J.; Melmed, S. and Biller, B.M. and Pasireotide Acromegaly Study Group. (2010) Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: A randomized, multicenter, phase II trial. J. Clin. Endocrinol. Metab., 95, 2781-2789.
98. Colao, A.; Bronstein, M.D.; Freda, P.; Gu, F.; Shen, C.C; Gadelha, M.; Fleseriu, M.; van der Lely, A.; Farrall, A.; Hermosillo Reséndiz, K.; Ruffin, M.; Chen, Y. and Sheppard, M. (2014) Pasireotide versus octreotide in acromegaly: A head-to-head superiority study. J. Clin. Endocrinol. Metab., 99, 791-799.
99. Tuvia, S.; Atsmon, J.; Teichman, S.; Katz, S.; Salama, P.; Pelled, D.; Landau, I.; Karmeli, I.; Bidlingmaier, M.; Strasburger, C.J.; Kleinberg, D.L.; Melmed, S. and Mamluk, R. (2012) Oral octreotide absorption in human subjects: Comparable pharmacokinetics to parenteral octreotide and effective growth hormone suppression. J. Clin. Endocrinol. Metab., 97, 2362-2369.
100. Stormann, S. and Schopohl, J. (2014) Emerging drugs for acromegaly. Expert Opin. Emerg. Drugs, 19, 79-97.
101. Osamura, R.Y.; Kajiya, H.; Takei, M.; Egashira, N.; Tobita, M.; Takekoshi, S. and Teramoto, A. (2008) Pathology of human pituitary adenomas. Histochem. Cell Biol., 130, 495-507.
102. Colao, A.; Ferone, D.; Marzullo, P.; Di Sarno, A.; Cerbone, G.; Sarnacchiaro, F.; Cirillo, S.; Merola, B. and Lombardi, G. (1997) Effect of different dopaminergic agents in the treatment of acromegaly. J. Clin. Endocrinol. Metab., 82, 518-523.
103. Abs, R.; Verhelst. J.; Maiter, D.; Van Acker, K.; Nobels, F.; Coolensee, J.L.; Mahler, C. and Beckers, A. (1998) Cabergoline in the treatment of acromegaly: a study in 64 patients. J. Clin. Endocrinol. Metab., 83, 374-378.
104. Sandret, L.; Maison, P. and Chanson, P. (2011) Place of cabergoline in acromegaly: A meta-analysis. J. Clin. Endocrinol. Metab., 96, 1327-1338.
105. Vilar, L.; Azevedo, M.F.; Naves, L.A.; Casulari, L.A.; Albuquerque, J.L.; Montenegro, R.M.; Montenegro, R.M. Jr.; Figueiredo, P.; Nascimento, G.C. and Faria, M.S. (2011) Role of the addition of cabergoline to the management of acromegaly patients resitant to long-term treatment with octreotide LAR. Pituitary, 14, 148-156.
106. Zanettini, R; Antonini, A; Gatto, G; Gentile, R; Tesei, S. and Pezzoli G. (2007) Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N. Engl. J. Med., 356, 39-46.
107. Schade, R; Andersohn, F; Suissa, S; Haverkamp, W. and Garbe, E. (2007) Dopamine agonists and the risk of cardiac-valve regurgitation. N. Engl. J. Med., 356, 29-38.
108. Auriemma, R.S; Pivonello, R; Perone, Y; Grasso, L.F; Ferreri, L; Simeoli, C; Lacuaniello, D; Gasperi, M. and Colao, A. (2013) Safety of long-term treatment with cabergoline on cardiac-valve disease in patients with prolactinomas. Eur. J. Endocrinol., 169, 359-366.
109. Maione, L.; Garcia, C.; Bouchachi, A.; Kallel, N.; Maison, P.; Salenave, S.; Young, J.; Assayag, P. and Chanson, P. (2012) No evidence of a detrimental effect of cabergoline therapy on cardiac valves in patients with acromegaly. J. Clin. Endocrinol. Metab., 97, E1714-E1719.
110. Rocheville, M.; Lange, D.C.; Kumar, U.; Patel, R.C. and Patel, Y.C. (2000) Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity. Science, 288, 154-157.
111. Ren, S.G.; Kim, S.; Taylor, J.; Dong, J.; Moreau, J.P.; Culler, M.D. and Melmed, S. (2003) Suppression of rat and human growth hormone and prolactin secretion by a novel somatostatin/ dopaminergic chimeric ligand. J. Clin. Endocrinol. Metab., 88, 5414-5421.
112. Jaquet, P.; Gunz, G.; Saveanu, A.; Dufour, H.; Taylor, J.; Dong, J.; Kim, S.; Moreau, J.P.; Enjalbert, A. and Culler, M.D. (2005) Efficacy of chimeric molecules directed towards multiple somatostatin and dopamine receptors on inhibition of GH and prolactin secretion from GH-secreting pituitary adenomas classified as partially responsive to somatostatin analog therapy. Eur. J. Endocrinol., 153, 135-141.
113. Mercado, M.; Davila, N.; McLeod, J.F. and Baumann, G. (1994) Distribution of growth hormone receptor messenger ribonucleic acid containing and lacking exon 3 in human tissues. J. Clin. Endocrinol. Metab., 78, 731-735.
114. Kopchick, J.J.; Parkinson, C.; Stevens, E.C. and Trainer, P.J. (2002) Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly. Endocr. Rev., 23, 623-646.
115. Kopchick, J.J. (2003) Discovery and development of a new class of drugs: GH antagonists. J. Endocrinol. Invest., 26(10 Suppl), 16-26.
116. Ross, R.J.; Leung, K.C.; Maamra, M.; Bennett, W.; Doyle, N.; Waters, M.J. and Ho, K.K. (2001) Binding and functional studies with the growth hormone receptor antagonist, B2036-PEG (pegvisomant), reveal effects of pegylation and evidence that it binds to a receptor dimer. J. Clin. Endocrinol. Metab., 86, 1716- 1723.
117. Maamra, M.; Kopchick, J.J.; Strasburger, C.J. and Ross, R.J. (2004) Pegvisomant, a growth hormone-specific antagonist, undergoes cellular internalization. J. Clin. Endocrinol. Metab., 89, 4532-4537.
118. Trainer, P.J.; Drake, W.M.; Katznelson, L.; Freda, P.U.; Herman- Bonert, V.; van der Lely, A.J.; Dimaraki, E.V.; Stewart, P.M.; Friend, K.E.; Vance, M.L.; Besser, G.M.; Scarlett, J.A.; Thorner, M.O.; Parkinson, C.; Klibanski, A.; Powell, J.S.; Barkan, A.L.; Sheppard, M.C.; Maldonado, M.; Rose, D.R.; Clemmons, D.R.; Johannsson, G.; Bengtsson, B.A.; Stavrou, S.; Kleinberg, D.L.; Cook, D.M.; Phillips, L.S.; Bidlingmaier, M.; Strasburger, C.J.; Hackett, S.; Zib, K.; Bennett, W.F. and Davis, R.J. (2000) Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N. Engl. J. Med., 342, 1171-1177.
119. van der Lely, A.J.; Hutson, R.K.; Trainer, P.J.; Besser, G.M.; Barkan, A.L.; Katznelson, L.; Klibanski, A.; Herman-Bonert, V.; Melmed, S.; Vance, M.L.; Freda, P.U.; Stewart, P.M.; Friend, K.E.; Clemmons, D.R.; Johannsson, G.; Stavrou, S.; Cook, D.M.; Phillips, L.S.; Strasburger, C.J.; Hackett, S.; Zib, K.A.; Davis, R.J.; Scarlett, J.A. and Thorner, M.O. (2001) Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet, 358, 1754-1759.
120. Schreiber, I.; Buchfelder, M.; Droste, M.; Forssmann, K.; Mann, K.; Saller, B. and Starsburger, C.J. (2006) Tretament of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: safety and efficacy evaluation from the German Pegvisomant Observational Study. Eur. J. Endocrinol., 156, 75-82.
121. Trainer, P.J. (2009) Acrostudy: The first 5 years. Eur. J. Endocrinol., 161, S19-S24.
122. Van der Lely, A.J.; Biller, B.M.; Brue, T.; Buchfelder, M.; Ghigo, E.; Gomez, R.; Hey-Hadavi, J.; Lundgren, F.; Rajicic, N.; Strasburger, C.J.; Webb, S.M. and Koltowska-Häggström, M. (2012) Long-term safety of pegvisomant in patients with acromegaly: comprehensive review of 1288 subjects in ACROSTUDY. J. Clin. Endocrinol. Metab., 97, 1288-1297.
123. Biering, H.; Saller, B.; Bauditz, J.; Pirlich, M.; Rudolph, B.; Johne, A.; Buchfelder, M.; Mann, K.; Droste, M.; Schreiber, I.; Lochs, H.; Strasburger, C.J. and German pegvisomant investigators. (2006) Elevated transaminases during medical treatment of acromegaly: a review of the German pegvisomant surveillance experience and a report of a patient with histologically proven chronic mild active hepatitis. Eur. J. Endocrinol., 154, 213-220.
124. Drake, W.M.; Rowles, S.V.; Roberts, M.E.; Fode, F.K.; Besser, G.M.; Monson, J.P. and Trainer, P.J. (2003) Insulin sensitivity and glucose tolerance improve in patients with acromegaly converted from depot octreotide to pegvisomant. Eur. J. Endocrinol., 149, 521-527.
125. Jehle, S.; Reyes, C.M.; Sundeen, R.E. and Freda, P.U. (2005) Alternate-day administration of pegvisomant maintains normal serum insulin-like growth factor-I levels in patients with acromegaly. J. Clin. Endocrinol. Metab., 90, 1588-1593.
126. Feenstra, J.; de Herder, W.W.; ten Have, S.M.; van den Beld, A.W.; Feelders, R.A.; Janssen, J.A. and van der Lely, A.J. (2005) Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly. Lancet, 365, 1644-1646.
127. Jørgensen, J.O.; Feldt-Rasmussen, U.; Frystyk, J.; Chen, J.W.; Kristensen, L.; ØHagen, C. and Ørskov, H. (2005) Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist. J. Clin. Endocrinol. Metab., 90, 5627-5631.
128. Neggers, S.J.; van Aken, M.O.; Janssen, J.A.; Feelders, R.A.; de Herder, W.W. and van der Lely, A.J. (2007) Long-term efficacy and safety of combined treatment of somatostatin analogs and pegvisomant in acromegaly. J. Clin. Endocrinol. Metab., 92, 4598- 4601.
129. Higham, C.E.; Atkinson, A.B.; Aylwin, S.; Bidlingmaier, M.; Drake, W.M.; Lewis, A.; Martin, N.M.; Moyes, V.; Newell-Price, J. and Trainer, P.J. (2012) Effective combination treatment with cabergoline and low dose pegvisomant in active acromegaly: A prospective clinical trial. J. Clin. Endocrinol. Metab., 97, 1187-1193.
130. Barkan, A.; Bronstein, M.; Bruno, O.D.; Cob, A.; Espinosa de los Monteros, A.L.; Gadelha, M.; Garavito, G.; Guitelman, M.; Mangupli, R.; Mercado, M.; Portocarrero, L. and Sheppard, M. (2010) Management of acromegaly in Latinamerica. Pituitary, 13, 168-175.
131. Minniti, G.; Scaringi, C. and Enrici, R.M. (2011) Radiation techniques for acromegaly. Radiation Oncology, 6, 167.
132. Ayuk, J.; Clayton, R.N.; Holder, G.; Sheppard, M.C.; Stewart, P.M. and Bates, A.S. (2004) Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor 1 concentrations predict excess mortality in patients with acromegaly. J. Clin. Endocrinol. Metab., 89, 1613-1617.
133. Arosio, M.; Reimondo, G.; Malchiodi, E.; Berchialla, P.; Borraccino, A.; De Marinis, L.; Pivonello, R.; Grottoli, S.; Losa, M.; Cannavò, S.; Minuto, F.; Montini, M.; Bondanelli, M.; De Menis, E.; Martini, C.; Angeletti, G.; Velardo, A.; Peri, A.; Faustini-Fustini, M.; Tita, P.; Pigliaru, F.; Borretta, G.; Scaroni, C.; Bazzoni, N.; Bianchi, A.; Appetecchia, M.; Cavagnini, F.; Lombardi, G.; Ghigo, E.; Beck-Peccoz, P.; Colao, A.; Terzolo, M. and Italian Study Group of Acromegaly. (2012) Predictors of morbidity and mortality in acromegaly: and Italian Surrey. Eur. J. Endocrinol., 167, 189-198.
134. Minniti, G.; Jaffrain-Rea, M.L.; Osti, M.; Esposito, V.; Santoro, A.; Solda, F.; Gargiulo, P.; Tamburrano, G. and Enrici, R.M. (2005) The long-term efficacy of conventional radiotherapy in patients with GH-secreting pituitary adenomas. Clin. Endocrinol., 62, 210- 216.
135. Jenkins, P.J.; Bates, P.; Carson, M.N.; Stewart, P.M. and Wass, J.A. (2006) Conventional pituitary irradiation is effective in lowering serum growth hormone and insulin-like growth factor 1 in patients with acromegaly. J. Clin. Endocrinol. Metab., 91, 1239-1245.
136. Gonzalez, B.; Vargas, G.; Espinosa de los Monteros, A.L.; Sosa, E. and Mercado, M. (2011) Efficacy and safety of radiotherapy in acromegaly. Arch Med. Res., 42, 48-52.
137. Minniti, G.; Scaringi, C.; Amelio, D. and Enrici, R.M. (2012) Stereotactic irradiation of GH-secreting pituitary adenomas. International J. Endocrinol., 2012, 482861.
138. Losa, M.; Giola, L.; Picozzi, P.; Franzin, A.; Valle, M.; Giovanelli, M. and Mortini, P. (2008) The role of stereotactic radiotherapy in patients with GH-secreting pituitary adenomas. J. Clin. Endocrinol. Metab., 93, 2546-2552.
139. Ronchi, C.L.; Attanasio, R.; Verrua, E.; Cozzi, R.; Ferrante, E.; Loli, P.; Montefusco, L.; Motti, E.; Ferrari, D.I.; Giugni, E.; Beck- Peccoz, P. and Arosio, M. (2009) Efficacy and tolerability of gamma knife radiosurgery in acromegaly: a 10-year follow-up study. Clin. Endocrinol., 71, 846-852.